Palatin Technologies, Inc. (0KF3.L) LSE

9.40

+0.82(+9.56%)

Updated at September 22 03:25PM

Currency In USD

Palatin Technologies, Inc.

Address

Cedar Brook Corporate Center

Cranbury, NJ 08512

United States of America

Phone

609 495 2200

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

30

First IPO Date

January 29, 2018

Key Executives

NameTitlePayYear Born
Dr. Carl Spana Ph.D.Co-Founder, President, Chief Executive Officer & Director1.07M1962
Mr. Stephen T. Wills CPA, MSTChief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer & Secretary1.1M1957
Mr. Robert JordanSenior Vice President of Program Operations0N/A
Mr. Stephen A. Slusher Esq.Chief Legal Officer0N/A
Burns McClellanVice President of Investor Relations0N/A
Dr. Michael B. Raizman M.D.Chief Medical Officer0N/A
Mr. James E. Hattersley B.A., M.S.Senior Vice President of Business Development01960
Mr. John Dodd Ph.D.Senior Vice President of Preclinical Development0N/A

Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.